Thyrocare Technologies Limited (THYROCARE.BO)
- Previous Close
907.65 - Open
880.75 - Bid 944.00 x --
- Ask 942.50 x --
- Day's Range
878.20 - 945.00 - 52 Week Range
570.75 - 1,053.05 - Volume
13,660 - Avg. Volume
6,702 - Market Cap (intraday)
49.852B - Beta (5Y Monthly) 0.38
- PE Ratio (TTM)
54.95 - EPS (TTM)
17.10 - Earnings Date Jul 21, 2025 - Jul 25, 2025
- Forward Dividend & Yield 18.00 (1.92%)
- Ex-Dividend Date Aug 16, 2024
- 1y Target Est
1,007.50
Thyrocare Technologies Limited provides diagnostic testing services to patients, laboratories, and hospitals in India. It operates through three segments: Diagnostic Testing Services, Imaging Services, and Others. The company conducts various medical diagnostic tests and profiles of tests that focuses on early detection and management of disorders and diseases, including thyroid, growth, metabolism, auto-immunity, diabetes, anaemia, cardiovascular, infertility, and various infectious diseases. Its profiles of tests include profiles of tests administered under its Aarogyam brand, which offers patients a suite of wellness and preventive health care tests. The company sells glucometer and glucostrips under the brand name Sugarscan; consumables; and radiopharmaceutical products. Thyrocare Technologies Limited was founded in 1996 and is based in Navi Mumbai, India. Thyrocare Technologies Limited is a subsidiary of Docon Technologies Private Limited.
www.thyrocare.comRecent News: THYROCARE.BO
View MorePerformance Overview: THYROCARE.BO
Trailing total returns as of 5/9/2025, which may include dividends or other distributions. Benchmark is S&P BSE SENSEX (^BSESN) .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: THYROCARE.BO
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: THYROCARE.BO
View MoreValuation Measures
Market Cap
49.77B
Enterprise Value
48.08B
Trailing P/E
55.01
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
7.32
Price/Book (mrq)
9.11
Enterprise Value/Revenue
7.00
Enterprise Value/EBITDA
23.60
Financial Highlights
Profitability and Income Statement
Profit Margin
13.31%
Return on Assets (ttm)
12.63%
Return on Equity (ttm)
16.89%
Revenue (ttm)
6.87B
Net Income Avi to Common (ttm)
915.1M
Diluted EPS (ttm)
17.10
Balance Sheet and Cash Flow
Total Cash (mrq)
1.92B
Total Debt/Equity (mrq)
4.51%
Levered Free Cash Flow (ttm)
1.47B